A5073638727- Hematopoietic Stem Cell Transplantation
- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Immune Cell Function and Interaction
- Acute Myeloid Leukemia Research
- T-cell and B-cell Immunology
- Neuroblastoma Research and Treatments
- Polyomavirus and related diseases
- Complement system in diseases
- Cytomegalovirus and herpesvirus research
- Blood groups and transfusion
- Mesenchymal stem cell research
- Immunotherapy and Immune Responses
- Childhood Cancer Survivors' Quality of Life
- Chronic Myeloid Leukemia Treatments
- Cancer therapeutics and mechanisms
- Corneal Surgery and Treatments
- Chronic Lymphocytic Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Lymphoma Diagnosis and Treatment
- Platelet Disorders and Treatments
- Viral Infectious Diseases and Gene Expression in Insects
- Virus-based gene therapy research
- Medical and Biological Ozone Research
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology
2015-2024
Ministry of Health of the Russian Federation
2015-2024
John Wiley & Sons (United States)
2016
Hudson Institute
2016
Russian Children's Clinical Hospital
2010-2014
Alpha/beta T cell and CD19 depletion are used to improve the outcomes of hematopoietic stem transplantation (HSCT). We evaluated burden cytomegalovirus (CMV) Epstein-Barr virus (EBV) in pediatric patients after this HSCT type. A cohort 182 with malignant (n = 114) or nonmalignant 68) disorders was transplanted from either matched unrelated 124) haploidentical 58) donors. The cumulative incidence CMV EBV viremia were 51% 33%, respectively. Acute graft-versus-host disease (GVHD) grades II IV,...
We evaluated the outcome of αβ T cell-depleted haploidentical hematopoietic stem cell transplantation (HSCT) in a cohort children with chemorefractory acute myelogenous leukemia (AML). Twenty-two patients either primary refractory (n = 10) or relapsed 12) AML active disease status received transplant from donors. The preparative regimen included cytoreduction fludarabine and cytarabine subsequent myeloablative conditioning treosulfan thiotepa. Antithymocyte globulin was substituted...
BACKGROUND The safety of blood component transfusions is still concern and the use pathogen reduction (PR) methods increasing. Limited data are available describing efficacy PR platelet (PLT) in children. We report results a retrospective evaluation prophylactic PLT units treated with riboflavin ultraviolet light pediatric patients malignant disorders. STUDY DESIGN AND METHODS A total 137 (PR, 51; control, 86) 432 141; 291) mean age 11 years were evaluated. primary clinical endpoint was...
Depletion of αβ T cells from the graft prevents graft-versus-host disease (GVHD) and improves outcome hematopoietic stem cell transplantation (HSCT) haploidentical donors. Delayed recovery adaptive immunity remains a problem, which can be approached by adoptive T-cell transfer. In randomized trial, we have assessed safety efficacy low-dose memory (CD45RA-depleted) donor lymphocytes (mDLI) after HSCT with depletion. Antithymocyte globulin (ATG) is viewed as an essential component preparative...
Acquired thrombotic thrombocytopenic (aTTP) purpura is a life-threatening condition that can lead to devastating thromboembolic events. Recently, caplacizumab has been shown rapidly restore platelet numbers and reduce the risk of severe end-organ damage when added plasma exchanges (PEXs) immunosuppression (IST). Here, we report outcomes in 3 children with aTTP who were treated combination PEXs IST. In all patients, count increased >15,000/mm 24 h normalized on day 4, whereas normalization...
Treatment of patients with high-risk neuroblastoma (NB) is a complex challenge, and it based on response to certain elements therapy. The development introduction new treatment approaches, such as GD2-targeted immunotherapy (IT), leads improved survival in this cohort patients. aim the study was retrospectively assess effectiveness therapy NB before IT into clinical practice. We analyzed data 151 stratified group who had received accordance modified NB2004 protocol German Society for...
The main goal is to optimize hematopoietic stem cell transplantation (HSCT) approach among adolescents and young adults with paroxysmal nocturnal hemoglobinuria (PNH) by means of Graft-versus-host disease (GVHD) post-transplant complications risk lowering.We report our experience HSCT from HLA-matched unrelated donors using TCR alfa/beta CD19 depletion in 5 pts (1M/4F) PNH, developed after successful immunosuppressive therapy (IST) acquired aplastic anemia (AA). Median age at the moment was...
Abstract Both acute GVHD and chronic remain the leading cause of morbidity death after allogeneic HSCT. We conducted a retrospective analysis comparing two GVHD‐prophylaxis regimens: 35 patients received “Regimen 1” (horse ATG, tacrolimus, methotrexate) 46 2” (rabbit rituximab, peritransplant bortezomib). All 81 with median age 9 (0.6‐23) years ALL (n = 31) or AML 50) in complete remission TCRαβ/CD19‐depleted transplants between May 2012 October 2016, from 40 HLA‐matched unrelated 41...
Implementation of the technique immunomagnetic selection requires procurement a large number CD34+ cells from haploidentical donors within single apheresis procedure. The release stem with granulocyte colony-stimulating factor (G-CSF) alone is unsatisfactory in donors, and plerixafor, CXCR4 chemokine receptor antagonist, could be used as an additional mobilization agent. aim our study was to examine whether lower dose plerixafor (0.12 mg/kg) can provide sufficient increase peripheral blood...
Hematopoietic stem cell transplantation (HSCT) is known to be most effective in cancer patients remission. In this paper, we analyzed a cohort of children with refractory acute myeloid leukemia (AML) order study the effectiveness HSCT such patients. The was approved by Independent Ethics Committee and Scientific Council Dmitry Rogachev National Medical Research Center Pediatric Hematology, Oncology Immunology conducted accordance principles Declaration Helsinki. All and/or their legal...